Jean-Jacques Kiladjian, MD, PhD | Authors


Data Support Momelotinib as a Differentiated Approach to Treating Myelofibrosis

January 22, 2021

JAK inhibitors designed for the treatment of myelofibrosis address the splenic response and constitutional symptoms associated with the disease, but the agents are inherently myelosuppressive and can exacerbate anemia and thrombocytopenia.

Evaluating Ruxolitinib With Pegylated Interferon Alfa-2a in Myelofibrosis

January 17, 2019

Jean-Jacques Kiladjian, MD, PhD, head of clinical investigation at Saint Louis Hospital in Paris, discusses the Ruxopeg trial, a phase I/II trial investigating the combination of ruxolitinib (Jakafi) with pegylated interferon alfa-2a in patients with myeloproliferative neoplasm (MPN)-associated myelofibrosis.